<DOC>
	<DOCNO>NCT02183077</DOCNO>
	<brief_summary>Study gain information percutaneous absorption meloxicam administration topical gel 7 day .</brief_summary>
	<brief_title>Pharmacokinetics Tolerability Meloxicam Gel Compared Meloxicam Tablets Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Meloxicam</mesh_term>
	<criteria>Healthy subject determine result screen Signed write informed consent accordance Good Clinical Practice local legislation Age &gt; = 18 &lt; = 50 year Broca &gt; = 20 % &lt; = + 20 % Any find medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder Chronic relevant acute infection Hypersensitivity meloxicam excipients nonsteroidal antirheumatic agent Intake drug long halflife ( &gt; 24 hour ) ( &lt; = 1 month prior administration trial ) Use drug might influence result trial ( &lt; = 10 day prior administration trial ) Participation another trial investigational drug ( &lt; = 2 month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke study day Known alcohol abuse Known drug abuse Blood donation ( &lt; = 1 month prior administration ) Excessive physical activity ( &lt; = 5 day prior administration ) History hemorrhagic diatheses History gastrointestinal ulcer , perforation bleed History bronchial asthma Any laboratory value outside normal range clinical relevance History dermatological disease Skin disease and/or skin lesion site plan application For female subject : Pregnancy Positive pregnancy test Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>